← All trials
NCT05776758
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Jan 31, 2025
- Completion date
- Jan 31, 2027
- First posted
- Mar 20, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 236
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ISTITUTO REGINA ELENALead sponsor
- ISTITUTO REGINA ELENAReponsible party - principal investigator
- ISTITUTO REGINA ELENASponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.